Gastrointestinal Cancers
Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial
Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.
Read more
Cancer
Targeting HER2 mutations in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Read more
Cancer
Investigating MDM2-p53 in cancer
Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.
Read more
Related press releases
August 27, 2024
Boehringer Ingelheim to unveil oncology research at WCLC
Links
TAKING CANCER ON
Episode 2: A Deep Dive Into Clinical Trials
TAKING CANCER ON
Episode 3: Collaborating Against Cancer
Human Health
Human Health partnering
Press Release
Boehringer Ingelheim signs license deal with A*STAR
Press Release
Boehringer Ingelheim Signs Option to Acquire Trutino Biosciences
Taking Cancer on: The Podcast
From early stage discovery to clinical trials and approval, we're Taking Cancer On. Click here to access the podcast homepage, where you will find all the available episodes.